Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mannitol increases plasma osmolality, drawing water from tissues into the intravascular space via osmotic gradient, thereby reducing intracranial pressure and promoting diuresis. Dextrose provides caloric support. Sodium chloride provides electrolytes.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Reduction of intracranial pressure (FDA approved),Promotion of diuresis in acute renal failure (FDA approved),Reduction of intraocular pressure (off-label),Cerebral edema (off-label),Enhancement of urinary excretion of toxic substances (off-label)
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous: 50 to 100 g (333-667 m L) initially, then 50 g (333 m L) every 4-6 hours to maintain urine output of 30-50 m L/hr. Administer as a 15% solution with dextrose 5% in 0.45% sodium chloride.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Mannitol: 0.5-1.5 hours in normal renal function; prolonged to 24-48 hours in anuria; dextrose: 1-2 hours; negligible for sodium chloride.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Mannitol is minimally metabolized in the liver; mainly excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis. Approximately 80% of mannitol is excreted in urine within 3 hours.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal excretion of unchanged mannitol: 80-90% within 24 hours; dextrose is fully metabolized; sodium chloride is renally excreted.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Mannitol: 0% (not bound to plasma proteins); dextrose: negligible; sodium chloride: not applicable.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Mannitol: 0.2-0.5 L/kg, primarily extracellular; dextrose: ~0.2 L/kg; sodium chloride distributes in extracellular fluid.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
IV: 100% for all components; no oral bioavailability for mannitol (<10% absorbed).
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). Use with caution in oliguria; monitor urine output and renal function.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific adjustment required; use with caution in severe hepatic impairment due to fluid and electrolyte balance concerns.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
200 mg/kg to 2 g/kg as a 15% solution intravenously over 2-6 hours, not to exceed 60 g in 24 hours. Adjust based on urine output and clinical response.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Start at lower end of dosing range; monitor renal function, fluid and electrolyte status due to age-related decline in renal function.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
No FDA boxed warning.
None.
Monitor serum electrolytes, renal function, and fluid balance,Risk of pulmonary edema or congestive heart failure in patients with cardiac disease,Risk of acute kidney injury or renal tubular necrosis with excessive doses or prolonged use,May cause fluid and electrolyte disturbances (e.g., hyponatremia, hyperkalemia),Use with caution in patients with impaired renal function,Intravenous administration: avoid extravasation, use large vein, monitor for phlebitis
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Anuria or severe renal impairment,Pulmonary edema or congestive heart failure,Active intracranial bleeding (except during craniotomy),Dehydration or hypovolemia,Known hypersensitivity to mannitol or any component
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No known food interactions. However, patients may require sodium restriction depending on their condition.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
No evidence of teratogenicity in animal studies. Use in pregnancy only if clearly needed. Mannitol crosses placenta; fetal effects may include electrolyte disturbances and dehydration. Avoid in first trimester unless benefit outweighs risk. In second and third trimesters, monitor for maternal pulmonary edema and fetal distress.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Mannitol likely excreted in breast milk due to low molecular weight. No M/P ratio available. Use with caution in lactating women; consider risk of infant dehydration or electrolyte imbalance. May suppress lactation due to diuretic effect.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Pregnancy increases glomerular filtration rate, potentially enhancing mannitol clearance. No specific dose adjustment guidelines; titrate to clinical response and serum osmolality. Monitor for hypovolemia and electrolyte disturbances. Use lowest effective dose.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Monitor urine output and serum sodium closely; mannitol can cause osmotic diuresis leading to hypernatremia or hyponatremia depending on fluid status. Administer via central line due to high osmolality; extravasation causes tissue necrosis. Contraindicated in anuria, pulmonary edema, and intracranial bleeding. Use with caution in renal impairment and heart failure.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This medication may increase urination; keep track of how much you urinate.,Report any chest tightness, difficulty breathing, or swelling.,You may experience dry mouth or thirst; maintain adequate fluid intake if allowed.,This solution is for intravenous use only; do not inject into muscle or under skin.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Mannitol increases plasma osmolality, drawing water from tissues into the intravascular space via osmotic gradient, thereby reducing intracranial pressure and promoting diuresis. Dextrose provides caloric support. Sodium chloride provides electrolytes.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% is: Intravenous: 50 to 100 g (333-667 m L) initially, then 50 g (333 m L) every 4-6 hours to maintain urine output of 30-50 m L/hr. Administer as a 15% solution with dextrose 5% in 0.45% sodium chloride.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% is classified as Category A/B. No evidence of teratogenicity in animal studies. Use in pregnancy only if clearly needed. Mannitol crosses placenta; fetal effects may include electrolyte disturbances and dehydrat. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.